Meeting
2022 ASCO Annual Meeting
Impact of clonal hematopoiesis on tumor control following radiation therapy.
Authors
Jacqueline Tao
Department of Medicine, New York-Presbyterian Weill Cornell, New York, NY
Jacqueline Tao , Jeremy Setton , Pablo Sanchez Vela , Anton Mikhailovich Safonov , Elizabeth Anne Comen , Lior Zvi Braunstein , Jorge S. Reis-Filho , Nadeem Riaz , Simon N. Powell , Ross L. Levine , Larry Norton , Atif J. Khan , Pedram Razavi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3145)
DOI
10.1200/JCO.2022.40.16_suppl.3145
Abstract #
3145
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
First Author: Jeffrey Lee Jensen
Poster
2018 ASCO Annual Meeting
Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.
First Author: Catherine Callaghan Coombs
Poster
2022 ASCO Annual Meeting
Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results.
First Author: Robin Harrington
Poster
2020 ASCO Virtual Scientific Program
Type of prior genotoxic insult determines the genomic characteristics of therapy-related acute myeloid leukemia.
First Author: Michael Ozga